Related Experiment Video
Updated: Apr 5, 2026
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Identification of potential therapeutic targets for melanoma using gene expression analysis
Abstract:
Metastatic melanoma represents a significant cause of death in patients with melanoma and the frequency is increasing. The aim of this study was to identify potential therapeutic targets for metastatic melanoma. Gene expression profile GSE44660 was downloaded from Gene Expression Omnibus database. A total of 22 samples were analyzed in our study, including 3 specimens of normal melanocytes, 12 specimens of melanoma LNM (lymph node metastasis) and 7 specimens of MBM (melanoma brain metastasis). DEGs (differentially expressed genes) in LNM and MBM were identified respectively using Limma package. GO (Gene Ontology) and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways analyses of common DEGs between two comparison groups were performed using DAVID, followed by cancer-related genes and transcription factor analysis. PPI (protein-protein interaction) network was constructed by STRING, and significant key genes were selected. Totally, 401 common DEGs were identified. Disease analysis showed that ICAM1 (intercellular adhesion molecule 1) and NBN (nibrin) were related to melanoma. In the PPI network, BIRC5 (baculoviral IAP repeat containing 5), BUB1 (BUB1 mitotic checkpoint serine/threonine kinase), GMNN (geminin, DNA replication inhibitor), AURKA (aurora kinase A), TOP2A (topoisomerase (DNA) II alpha) and BUB1B (BUB1 mitotic checkpoint serine/threonine kinase B) were with higher degree more than 50. ICAM1, NBN, BIRC5, BUB1, BUB1B, GMNN, AURKA and TOP2A may play key roles in the progression and development of melanoma. They may be used as specific therapeutic targets in the treatment of metastatic melanoma. However, further experiments are still needed to confirm our results.
Insights
Metastatic melanoma is a deadly disease. This study identified key genes like ICAM1 and BIRC5 involved in melanoma progression, suggesting they could be new therapeutic targets for metastatic melanoma treatment.
Area of Science:
- Oncology
- Genomics
- Bioinformatics
Background:
- Metastatic melanoma is an increasing cause of cancer mortality.
- Identifying novel therapeutic targets is crucial for improving patient outcomes.
Purpose of the Study:
- To identify potential therapeutic targets for metastatic melanoma.
- To analyze gene expression profiles and protein-protein interactions in metastatic melanoma.
Main Methods:
- Utilized Gene Expression Omnibus (GEO) dataset GSE44660, comparing normal melanocytes with melanoma lymph node metastasis (LNM) and melanoma brain metastasis (MBM).
- Identified differentially expressed genes (DEGs) using Limma, followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses.
- Constructed a protein-protein interaction (PPI) network using STRING to identify key genes, including ICAM1 and NBN, and highly connected genes like BIRC5, BUB1, GMNN, AURKA, TOP2A, and BUB1B.
Main Results:
- Identified 401 common DEGs between LNM and MBM.
- ICAM1 (intercellular adhesion molecule 1) and NBN (nibrin) were found to be associated with melanoma.
- Key genes BIRC5, BUB1, GMNN, AURKA, TOP2A, and BUB1B showed high connectivity in the PPI network, indicating their potential significance.
Conclusions:
- ICAM1, NBN, BIRC5, BUB1, BUB1B, GMNN, AURKA, and TOP2A are implicated in melanoma progression and development.
- These genes represent potential specific therapeutic targets for metastatic melanoma.
- Further experimental validation is required to confirm these findings.
